The TIGIT pathway has also been studied in CLL [48], and its expression was inversely correlated with time to first treatment and the B cell receptor (BCR) signaling capacity, as determined by BTK activity and cell proliferation [48]. Here, TIGIT is linked to B-cell chronic lymphocytic leukemia.